- Home
- OPK vs AUPH Comparison
OPK vs AUPH Comparison
Compare OPK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPK | AUPH |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.6B |
| IPO Year | 1995 | 1999 |
Fundamental Metrics
Financial Performance| Metric | OPK | AUPH |
|---|---|---|
| Price | $1.37 | $15.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $2.28 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 4.0M | 1.0M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $642,067,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $16.45 |
| P/E Ratio | ★ N/A | $29.12 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $1.11 | $6.55 |
| 52 Week High | $2.04 | $16.54 |
Technical Indicators
Market Signals| Indicator | OPK | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 46.12 |
| Support Level | $1.24 | $14.82 |
| Resistance Level | $1.33 | $15.98 |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 100.00 | 30.81 |
Price Performance
Historical ComparisonAbout OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.